[1] World health organization. WHO steps up action to improve access to safe blood[EB/OL].(2020-02-26). http://www.who.int/news/item/26-02-2020-who-steps-up-action-to-improve-access-to-safe-blood.
[2] International society of blood transfusion. patient blood management[EB/OL].(2019). http://www.isbtweb.org/working-parties/clinicaltransfusion/pbm-resource-chapters-1-5.
[3] AABB. AABB guide to patient blood management and blood utilization[EB/OL].(2020). http://www.aabb.org/aabb-store/product/aabb-guide-to-patient-blood-management-and-blood-utilization---print-15175351.
[4] National blood authority. patient blood management guidelines progress update: march 2021[EB/OL].(2021). http://www.blood.gov.au/pbm-guidelines-updates.
[5] TIBI P,MCCLURE R S,HUANG J P,et al.STS/SCA/AmSECT/SABM update to the clinical practice guidelines on patient blood management[J]. Ann Thorac Surg,2021,112(3):981-1004.
[6] 中国心胸血管麻醉学会血液管理分会. 心血管手术患者血液管理专家共识[J]. 中国输血杂志,2018,31(4):321-325.
[7] TOBIAN A A R,HEDDLE N M,WIEGMANN T L,et al. Red blood cell transfusion:2016 clinical practice guidelines from AABB[J]. Transfusion,2016,56(10):2627-2630.
[8] HÉBERT P C,WELLS G,BLAJCHMAN M A,et al. A multicenter,randomized,controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators,Canadian Critical Care Trials Group[J]. N Engl J Med,1999,340(6):409-417.
[9] HÉBERT P C,CARSON J L. Transfusion threshold of 7 g per deciliter—the new normal[J]. N Engl J Med,2014,371(15):1459-1461.
[10] CARSON J L,STANWORTH S J,ROUBINIAN N,et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion[J]. Cochrane Database Syst Rev,2016,10(10):CD002042.
[11] CARSON J L,STANWORTH S J,ALEXANDER J H,et al.Clinical trials evaluating red blood cell transfusion thresholds:an updated systematic review and with additional focus on patients with cardiovascular disease[J]. Am Heart J,2018,200:96-101.
[12] MUELLER M M,VAN REMOORTEL H,MEYBOHM P,et al.Patient blood management:recommendations from the 2018 Frankfurt consensus conference[J]. JAMA,2019,321(10):983-997.
[13] 国家卫生健康委员会. 临床输血技术规范[EB/OL].(2001-11-08).http://www.nhc.gov.cn/yzygj/s3589/200804/adac19e63a4f49acafab8e0885bf07e1.shtml.
[14] 孙楠,温转. 限制性输血策略对ICU患者临床预后的影响[J]. 中国输血杂志,2017,30(11):1259-1261.
[15] 邹娟. 围手术期限制性输血在单侧全膝关节置换术患者中的应用研究[J]. 实验与检验医学,2017,35(5):803-805.
[16] 方静,胡继军,马春梅,等. 急性上消化道出血患者不同输血策略的输血疗效评估[J]. 临床血液学杂志,2019,32(8):641-644.
[17] 李君,陈茂琼,王榜珍,等. 不同输血策略治疗早产儿贫血疗效分析[J]. 中华妇幼临床医学杂志(电子版),2021,17(2):166-170.
[18] STANWORTH S J,KILLICK S,MCQUILTEN Z K,et al.Red cell transfusion in outpatients with myelodysplastic syndromes:a feasibility and exploratory randomised trial[J]. Br J Haematol,2020,189(2):279-290.
[19] DOCHERTY A B,WALSH T S.Anemia and blood transfusion in the critically ill patient with cardiovascular disease[J]. Crit Care,2017,21(1):61.
[20] KLEIN H G,FLEGEL W A,NATANSON C.Red blood cell transfusion:precision vs imprecision medicine[J]. JAMA,2015,314(15):1557-1558.
[21] MØLLER A,NIELSEN H B,WETTERSLEV J,et al. Low vs high hemoglobin trigger for transfusion in vascular surgery:a randomized clinical feasibility trial[J]. Blood,2019,133(25):2639-2650.
[22] GOBATTO A L N,LINK M A,SOLLA D J,et al. Transfusion requirements after head trauma:a randomized feasibility controlled trial[J]. Crit Care,2019,23(1):89.
[23] ESTCOURT L J,MALOUF R,TRIVELLA M,et al. Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy,or both,with or without haematopoietic stem cell support[J]. Cochrane Database Syst Rev,2017,1(1):CD011305.
[24] TAY J,ALLAN D S,CHATELAIN E,et al.Liberal versus restrictive red blood cell transfusion thresholds in hematopoietic cell transplantation:a randomized,open label,phase Ⅲ,noninferiority trial[J]. J Clin Oncol,2020,38(13):1463-1473.
[25] MCQUILTEN Z K,POLIZZOTTO M N,WOOD E M,et al.Myelodysplastic syndrome incidence,transfusion dependence,health care use,and complications:an Australian population-based study 1998 to 2008[J]. Transfusion,2013,53(8):1714-1721.
[26] KILLICK S B,CARTER C,CULLIGAN D,et al.Guidelines for the diagnosis and management of adult myelodysplastic syndromes[J]. Br J Haematol,2014,164(4):503-525.
[27] Stanworth SJ, Estcourt LJ.When to transfuse and how much in hematologic malignancies[J]. Hematol Educ, 2014, 8(3):421-426.
[28] DE SWART L,SMITH A,FENAUX P,et al.7 Management of 1000 patients with low- and intermediate-1 risk myelodysplastic syndromes in the European LeukemiaNet MDS Registry[J]. Leuk Res,2011,35:S3.
[29] MO A,MCQUILTEN Z K,WOOD E M,et al.Red cell transfusion thresholds in myelodysplastic syndromes:a clinician survey to inform future clinical trials[J]. Intern Med J,2017,47(6):695-698.
[30] MALCOVATI L,DELLA PORTA M G,STRUPP C,et al. Impact of the degree of Anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)[J]. Haematologica,2011,96(10):1433-1440.
[31] BUCKSTEIN R J,PRICA A,LEBER B,et al.RBC-enhance:a randomized pilot feasibility trial of red cell transfusion thresholds in myelodysplastic syndromes[J]. Blood,2020,136(Supplement 1):3-4.
[32] DAVIS B A,ALLARD S,QURESHI A,et al.Guidelines on red cell transfusion in sickle cell disease. Part I:principles and laboratory aspects[J]. Br J Haematol,2017,176(2):179-191.
[33] MAZER C D,WHITLOCK R P,FERGUSSON D A,et al.Six-month outcomes after restrictive or liberal transfusion for cardiac surgery[J]. N Engl J Med,2018,379(13):1224-1233.
[34] DOCHERTY A B,O'DONNELL R,BRUNSKILL S,et al. Effect of restrictive versus liberal transfusion strategies on outcomes in patients with cardiovascular disease in a non-cardiac surgery setting:systematic review and meta-analysis[J]. BMJ,2016,352:i1351.
[35] DUCROCQ G,GONZALEZ-JUANATEY J R,PUYMIRAT E,et al. Effect of a restrictive vs liberal blood transfusion strategy on major cardiovascular events among patients with acute myocardial infarction and Anemia:the REALITY randomized clinical trial[J]. JAMA,2021,325(6):552-560.
[36] CHOLETTE J M,WILLEMS A,VALENTINE S L,et al.Recommendations on RBC transfusion in infants and children with acquired and congenital heart disease from the pediatric critical care transfusion and Anemia expertise initiative[J]. Pediatr Crit Care Med,2018,19(9S Suppl 1):S137-S148.
[37] VALENTINE S L,BEMBEA M M,MUSZYNSKI J A,et al.Consensus recommendations for RBC transfusion practice in critically ill children from the pediatric critical care transfusion and Anemia expertise initiative[J]. Pediatr Crit Care Med,2018,19(9):884-898.
[38] PELLEREY M,COUDERC A L,PAULY V,et al.Transfusion practices in geriatric short stay unit before and after the French national health authority guidelines of 2014[J]. Geriatr Psychol Neuropsychiatr Vieil,2018,16(4):367-375.
[39] Brunskill S J,Millette S L,Shokoohi A,et al. Red blood cell transfusion for people undergoing hip fracture surgery[J]. Cochrane Database Syst Rev,2015(4):CD009699.
[40] PINCHON D J,STANWORTH S J,DORÉE C,et al. Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review[J]. Am J Hematol,2009,84(10):671-677.
[41] ABEL G A,EFFICACE F,BUCKSTEIN R J,et al.Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS)[J]. Haematologica,2016,101(6):781-788.
[42] MAYSON E,SHAND A W,FORD J B.Single-unit transfusions in the obstetric setting:a qualitative study[J]. Transfusion,2016,56(7):1716-1722.
[43] NILSSON-EHLE H,BIRGEGÅRD G,SAMUELSSON J,et al. Quality of life,physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin Alfa ± filgrastim or erythrocyte transfusions[J]. Eur J Haematol,2011,87(3):244-252.
[44] LEZIN E S,KARAFIN M S,BRUHN R,et al.Therapeutic impact of red blood cell transfusion on anemic outpatients:the RETRO study[J]. Transfusion,2019,59(6):1934-1943.
[45] PENNINX B W J H,PAHOR M,CESARI M,et al. Anemia is associated with disability and decreased physical performance and muscle strength in the elderly[J]. J Am Geriatr Soc,2004,52(5):719-724.
[46] MURPHREE D H,KINARD T N,KHERA N,et al.Measuring the impact of ambulatory red blood cell transfusion on home functional status:study protocol for a pilot randomized controlled trial[J]. Trials,2017,18(1):153.
[47] MURPHY G J,PIKE K T,ROGERS C A,et al.Liberal or restrictive transfusion after cardiac surgery[J]. N Engl J Med,2015,372(11):997-1008.
[48] MCQUILTEN Z K,HIGGINS A M,BURNS K,et al.The cost of blood:a study of the total cost of red blood cell transfusion in patients with β-thalassemia using time-driven activity-based costing[J]. Transfusion,2019,59(11):3386-3395.
[49] ESCOBAR M A.Health economics in haemophilia:a review from the clinician's perspective[J]. Haemophilia,2010,16(Suppl 3):29-34. |
